Photocure sees strong Q3 2025 with double-digit revenue growth

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 134.1 million in Q3 2025, a 12% increase from NOK 120.1 million in Q3 2024, contributing to total revenues of NOK 135.0 million. EBITDA for the quarter reached NOK 10.2 million, up from NOK 5.0 million in the previous year. The company expects product revenue growth of 8% to 10% on a constant currency basis and an EBITDA improvement for the full year 2025.

Strategic initiatives in Q3 2025 included the installation of 14 new Saphira towers in the U.S. and the deployment of 6 additional mobile BLC towers by ForTec, bringing the total to 24. This expanded Photocure's active U.S. accounts to 373, a 23% increase year-over-year. In Europe, 49 Olympus Visera Elite III BLC systems were installed since Q1 2025. Post-quarter, Photocure partnered with Intelligent Scopes Corporation to develop AI software for BLC, aiming to enhance early-stage bladder cancer detection.

The company's cash and cash equivalents stood at NOK 247.8 million at the end of Q3 2025. Significant milestones include positive Phase III trial results for Cevira and ongoing regulatory reviews for Hexvix in China. Photocure remains focused on accelerating BLC adoption, expanding its global product portfolio in uro-oncology, and leveraging new technologies like AI for precision diagnostics.